====== Kevin Antoine Brown ======

{{ ::kevin-brown-180x180.jpeg?150|}}

**Kevin Antoine Brown** is a Canadian infectious disease epidemiologist and health services researcher at [[public_health_agencies:Public Health Ontario]] and the [[University of Toronto]]. 

He is notable during the [[COVID-19 pandemic]] due to his role on the [[Ontario COVID-19 Science Advisory Table]].

===== Education =====

Brown received his PhD in Epidemiology from the University of Toronto and his MSc in Biostatistics from the [[University of North Carolina]]. 

===== Career and Affiliations =====

==== ICES ====

Brown is an adjunct scientist at the [[Institute for Clinical Evaluative Sciences]] (ICES).

===== Research =====

He studies healthcare-associated infections and antimicrobial resistance, with a specialty in //Clostridiodes difficile//. His research has focused on creating reproducible indexes of antibiotic risk, understanding the role of built environment in infectious disease transmission, and documenting geographic variation in diagnosis of infections, prescribing of antibiotics, and outcomes.((//About Us.// Ontario COVID-19 Science Advisory Table. Retrieved March 11, 2022, from https://covid19-sciencetable.ca/about/#brown-kevin-antoine))

==== Funding ====

Brown has received research funding from the [[Canadian Institutes of Health Research]] (CIHR).((Brown, K. A. (2021). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://web.archive.org/web/20220108230040/https://covid19-sciencetable.ca/wp-content/uploads/2021/02/Declaration-of-Interest_Congregate-Care-Setting-Working-Group_Kevin-Brown_20211014.pdf)) ((Brown, K. A. (2021). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://covid19-sciencetable.ca/wp-content/uploads/2021/02/Declaration-of-Interest_Congregate-Care-Setting-Working-Group_Kevin-Brown.pdf))

He also received funding for [[COVID-19]] research from the COVID-19 Emergency Response Fund from the [[Ottawa Hospital]].((MacFadden, D. R., Brown, K., Buchan, S. A., Chung, H., Kozak, R., Kwong, J. C., Manuel, D., Mubareka, S., & Daneman, N. (2022). //Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications.// Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofac156))

The [[Ottawa Hospital]] has received funding for research from [[:pharmaceutical_companies:Pfizer]] for research on drugs for advanced lung cancer,((//Early phase clinical trials shows promising results in advanced lung cancer.// (2011, October 12). Ottawa Hospital Research Institute. https://archive.ph/QMO7q)) kidney transplant patients((Knoll, G. A., Kokolo, M. B., Mallick, R., Beck, A., Buenaventura, C. D., Ducharme, R., Barsoum, R., Bernasconi, C., Blydt-Hansen, T. D., Ekberg, H., Felipe, C. R., Firth, J., Gallon, L., Gelens, M., Glotz, D., Gossmann, J., Guba, M., Morsy, A. A., Salgo, R., & Scheuermann, E. H. (2014). //Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.// BMJ, 349(nov24 1), g6679–g6679. https://doi.org/10.1136/bmj.g6679)) ((Ganton, J. (2015, October 22). //Drugs commonly used in kidney transplant patients not as effective as previously thought.// Ottawa Hospital Research Institute. https://archive.ph/SGtWQ)) and blood clots in cancer patients.((Ganton, J., & Pulkinghorn, I. M. (2018, December 4). //Drug dramatically reduces risk of dangerous blood clots in cancer patients.// Ottawa Hospital Research Institute. https://archive.ph/n6N5h)) ((Carrier, M., Abou-Nassar, K., Mallick, R., Tagalakis, V., Shivakumar, S., Schattner, A., Kuruvilla, P., Hill, D., Spadafora, S., Marquis, K., Trinkaus, M., Tomiak, A., Lee, A. Y. Y., Gross, P. L., Lazo-Langner, A., El-Maraghi, R., Goss, G., Le Gal, G., Stewart, D., & Ramsay, T. (2019). //Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.// The New England Journal of Medicine, 380(8), 711–719. https://doi.org/10.1056/NEJMoa1814468))